Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Costa Mesa, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Official Title

A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer

Keywords

Advanced Solid Tumors, Non-small Cell Lung Cancer, BMS-986442, Nivolumab, Chemotherapy, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Paclitaxel, Docetaxel, Carboplatin, Taxane, Pemexetred, BMS-986442 + Nivolumab, BMS-986442 + Nivolumab + Docetaxel, BMS-986442 + Nivolumab + Carboplatin + Pemetrexed, BMS-986442 + Nivolumab + Carboplatin + Paclitaxel

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Participants must have a life expectancy of at least 3 months at the time of first dose.

You CAN'T join if...

  • Untreated symptomatic central nervous system metastases or leptomeningeal metastases.
  • Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts.
  • Participants with an active, known, or suspected autoimmune disease.

    Other protocol-defined inclusion/exclusion criteria apply.

Locations

  • University of California, Irvine (UCI) Health Cancer Center - Newport/Costa Mesa not yet accepting patients
    Costa Mesa California 92627 United States
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center accepting new patients
    Orange California 92868 United States
  • University of Texas MD Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
ID
NCT05543629
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 225 study participants
Last Updated